FUNDAMENTALS |
MarketCap: |
5 149.65 mill
|
EPS: |
-19.98
|
P/E: |
-12.95
|
Earnings Date: |
May 06, 2024 |
SharesOutstanding: |
19.90 mill
|
Avg Daily Volume: |
0.565 mill
|
RATING
2024-03-27 |
B-
|
Sell
|
RATINGS |
Rating CashFlow: |
Strong Sell
|
|
Return On Equity: |
Strong Sell
|
|
Return On Asset: |
Sell
|
|
DE: |
Buy
|
|
P/E: |
Strong Sell
|
|
Price To Book: |
Strong Buy
|
|
QUARTER GROWTHS |
|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | | | | | |
Ebit | | | | | | |
Asset | | | | | | |
Debt | | | | | | |
PE RATIO: COMPANY / SECTOR |
0.00x
|
Company: PE -12.95 | sector: PE -3.05
|
PE RATIO: COMPANY / INDUSTRY |
-2.20x
|
Company: PE -12.95 | industry: PE 5.88
|
DISCOUNTED CASH FLOW VALUE |
$-0.925
(-100.36%)
$-259.73
|
Date: 2024-03-28
|
Expected Trading Range (DAY) |
$ 241.85 - 275.77
( +/- 6.55%)
|
ATR Model: 14 days
|
Insider Trading
Date |
Person |
Action |
Amount |
type |
2024-03-21 | Baker Bros. Advisors Lp | Buy | 970 951 | Common Stock Warrant (right to buy) |
2024-03-21 | Baker Bros. Advisors Lp | Buy | 86 741 | Common Stock Warrant (right to buy) |
2024-03-11 | Dier Mardi | Sell | 0 | Common Stock |
2024-03-11 | Dier Mardi | Sell | 8 875 | Market Stock Unit |
2024-03-11 | Dier Mardi | Sell | 13 353 | Stock Option (Right to Buy) |
INSIDER POWER |
-3.59
|
Last
100 transactions |
Buy:
1 310 453 | Sell:
1 604 345 |
Forecast:
16:00 - $258.75
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $258.75
Forecast 2: 16:00 - $258.75
Forecast 3: 16:00 - $258.75
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
MACD |
|
Volume Signals |
Price |
$258.81 (4.52% )
|
Volume |
0.399 mill
|
Avg. Vol. |
0.565 mill
|
% of Avg. Vol |
70.65 %
|
Signal 1: |
|
Signal 2: |
|
Last 10 Buy & Sell Signals For MDGL
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date |
Signal |
@ |
Closed |
% |
Feb 8 - 15:35 | sell | $171.59 | N/A | Active |
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.